Evidence map›Paper›PMID 39026059›Full record

ReviewCell biochemistry and biophysics2024

Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer.

Seyed Hamed Jafari, Zahra Sadat Lajevardi, Mohammad Masoud Zamani Fard, Ameneh Jafari, Soroush Naghavi, Fatemeh Ravaei, Seyed Pouya Taghavi, Kimia Mosadeghi, Fatemeh Zarepour, Maryam Mahjoubin-Tehran and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Seyed Hamed JafariMedical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra Sadat LajevardiSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Mohammad Masoud Zamani FardSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Ameneh JafariChronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Soroush NaghaviStudent Research Committee, Iran University of Medical Sciences, Tehran, Iran.
Fatemeh RavaeiSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Seyed Pouya TaghaviSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Kimia MosadeghiSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Fatemeh ZarepourSchool of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Maryam Mahjoubin-TehranSchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Neda RahimianEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran; Department of Internal Medicine, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran. Rahimian.n@iums.ac.ir.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. H.mirzaei2002@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PaC) incidence is increasing, but our current screening and diagnostic strategies are not very effective. However, screening could be helpful in the case of PaC, as recent evidence shows that the disease progresses gradually. Unfortunately, there is no ideal screening method or program for detecting PaC in its early stages. Conventional imaging techniques, such as abdominal ultrasound, CT, MRI, and EUS, have not been successful in detecting early-stage PaC. On the other hand, biomarkers may be a more effective screening tool for PaC and have greater potential for further evaluation compared to imaging. Recent studies on biomarkers and artificial intelligence (AI)-enhanced imaging have shown promising results in the early diagnosis of PaC. In addition to proteins, non-coding RNAs are also being studied as potential biomarkers for PaC. This review consolidates the current literature on PaC screening modalities to provide an organized framework for future studies. While conventional imaging techniques have not been effective in detecting early-stage PaC, biomarkers and AI-enhanced imaging are promising avenues of research. Further studies on the use of biomarkers, particularly non-coding RNAs, in combination with imaging modalities may improve the accuracy of PaC screening and lead to earlier detection of this deadly disease.

Indexed as

Biomarkers, TumorPancreatic NeoplasmsArtificial IntelligenceEarly Detection of CancerHumansMagnetic Resonance ImagingRNA, UntranslatedBiomarkers, TumorRNA, UntranslatedBiochemical biomarkersImaging techniquesPancreatic cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.